Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (111-120 of 216) with videos related to

Pageof 22
Sort By:
JCO Precision Oncology|June 7, 2023
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck CancerHannah Y Chen, Weilu Zhao, Shorook Na'ara, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
The Lancet. Oncology|January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based ChemotherapyPadmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
Cancer Immunology Research|May 20, 2024
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and MyositisBilal A Siddiqui, Nicolas L Palaskas, Sreyashi Basu, et al.
The Journal of Clinical Investigation|February 27, 2018
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapyYared Hailemichael, Amber Woods, Tihui Fu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsPadmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, et al.
Pageof 22

Showing results (111-120 of 216) with videos related to

Sort By:
Pageof 22
JCO Precision Oncology|June 7, 2023
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck CancerHannah Y Chen, Weilu Zhao, Shorook Na'ara, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
The Lancet. Oncology|January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based ChemotherapyPadmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
Cancer Immunology Research|May 20, 2024
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and MyositisBilal A Siddiqui, Nicolas L Palaskas, Sreyashi Basu, et al.
The Journal of Clinical Investigation|February 27, 2018
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapyYared Hailemichael, Amber Woods, Tihui Fu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2019
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsPadmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, et al.
Pageof 22